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Abstract
Background: Human immunodeficiency virus type 1 (HIV-1) can be inhibited by means of RNA
silencing or interference (RNAi) using synthetic short interfering RNAs (siRNAs) or gene
constructs encoding short hairpin RNAs (shRNAs) or long hairpin RNAs (lhRNAs). The use of
siRNA and shRNA as antiviral therapeutic is limited because of the emergence of viral escape
mutants. This problem is theoretically prevented by intracellular expression of lhRNAs generating
multiple siRNAs that target the virus simultaneously, thus reducing the chance of viral escape.
However, gene constructs encoding lhRNA molecules face problems with delivery to the right cells
in an infected individual. In order to solve this problem, we constructed an HIV-1 variant with a
300 bp long hairpin structure in the 3' part of the genome corresponding to the Nef gene (HIV-
lhNef).
Results: Intriguingly, HIV-lhNef potently inhibited wild-type HIV-1 production in trans. However,
HIV-lhNef demonstrated a severe production and replication defect, which we were able to solve
by selecting spontaneous virus variants with truncated hairpin structures. Although these escape
variants lost the ability to trans-inhibit HIV-1, they effectively outgrew the wild-type virus in
competition experiments in SupT1 cells.
Conclusion: Expression of the lhNef hairpin within the HIV-1 genome results in potent trans-
inhibition of wild-type HIV-1. Although the mechanism of trans-inhibition is currently unknown, it
remains of interest to study the molecular details because the observed effect is extremely potent.
This may have implications for the development of virus strains to be used as live-attenuated virus
vaccines.
Background
RNA interference (RNAi) has been used to inhibit the rep-
lication of a wide range of viruses including the human
immunodeficiency virus type 1 (HIV-1), hepatitis C virus
(HCV), hepatitis B virus (HBV), dengue virus, poliovirus,
influenza virus A, coronaviruses, herpesviruses, and picor-
naviruses [1,2]. Due to its sequence specificity, RNAi is a
potentially selective method for intracellular immuniza-
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tion against HIV-1 infection. RNAi-mediated suppression
of HIV-1 replication has been accomplished by synthetic
small interfering RNAs (siRNAs) in a transient manner [3-
6] and by shRNA expression vectors in stably transfected
cells [7-9]. Despite potent inhibition, the use of both
approaches as therapeutic antiviral is limited because of
the rapid emergence of HIV-1 escape mutants [9-11].
Strategies to reduce the chance of viral escape include the
simultaneous use of multiple siRNAs [12,13], the intracel-
lular expression of a second generation of escape-antici-
pating shRNAs [14], or microRNA-based double-stranded
RNAs (miRNAs), which do not require perfect sequence
complementarity for inhibition [15,16].
An alternative method to inhibit HIV-1 is the use of gene
constructs encoding HIV-1-specific long hairpin RNAs
(lhRNAs, transcripts folding an extended hairpin struc-
ture) or long double-stranded RNAs (dsRNAs, two com-
plementary transcripts that form an extended duplex).
These molecules should yield multiple effective siRNAs
upon intracellular processing [6,17,18]. However, lhRNA
approaches raise concerns about induction of the dsRNA-
triggered interferon (IFN) response. Others and we have
shown that endogenously expressed lhRNA and dsRNA
can inhibit HIV-1 production without induction of the
innate antiviral response [18-21]. In fact, most reports on
IFN induction by long dsRNAs in mammalian cells are
based on transfection of cells with in vitro synthesized
dsRNAs [22,23]. Apparently, endogenously produced
dsRNA is less active than exogenous dsRNA in inducing
the IFN response.
Several antiviral approaches using extended lhRNA and
long dsRNA molecules have been reported in plant and
insect cells that lack the innate antiviral IFN response.
Transient expression of DNA constructs encoding virus-
specific dsRNA in plant protoplasts or insect cells partially
protects the cells from infection by the homologous virus
[23,24]. Stable expression of such constructs renders the
cells resistant to infection [25,26]. lhRNA can inhibit HIV-
1 production under certain conditions, without induction
of the IFN response [6,17,18]. Ideally, a single lhRNA
should generate multiple effective siRNAs upon intracel-
lular processing, providing more durable inhibition of
HIV-1 than a single shRNA. An additional advantage of
lhRNA inhibitors is that it does not require pre-determina-
tion of the optimal shRNAs and corresponding HIV-1 tar-
get sequences because multiple effective siRNAs will be
produced. A potential disadvantage of the use of lhRNA as
therapeutic is that the generation of multiple siRNAs will
be more likely to cause off-target effects.
We have previously reported strong inhibition of HIV-1
production using gene constructs encoding HIV-specific
lhRNAs and dsRNA in transient transfection assays [18].
An alternative for stable expression of shRNAs is a condi-
tionally replicating HIV-1-based virus, which was previ-
ously used by us to deliver an antiviral shRNA cassette
into HIV-1 susceptible target cells [27]. In the current
study, we constructed the HIV-lhNef variant, which con-
tains a 300 bp extended hairpin structure at the 3' genome
position of the Nef gene of the otherwise wild-type HIV-1.
We tested this HIV-lhNef for its capacity to inhibit the pro-
duction of wild-type virus. Intriguingly, HIV-lhNef
potently inhibited wild-type HIV-1 production in trans.
However, HIV-lhNef demonstrated a severe production
and replication defect, which we were able to solve by
selecting spontaneous, escape viruses.
Results
The HIV-lhNef variants
We previously described the construction of the HIV-
lhNef virus variant [28], which contains a 300 bp
extended hairpin structure (Fig. 1A). The hairpin structure
is present in the full-length genomic RNA and all spliced
mRNAs. This structure induced a severe virus production
and replication defect. Similarly, we were not able to
obtain stable expression of the lhRNA inhibitor from a
lentiviral vector (results not shown), probably due to
problems in reverse transcription of the excessively stable
hairpin structure [29]. The presence of the lhNef insert
resulted in a dramatic drop of the viral transduction titer,
possibly also due to self-targeting of Nef/LTR sequences in
the vector genome. Unlike the non-replicating lentiviral
vector, the HIV-lhNef virus could generate spontaneous
variants by evolution. Indeed, replicating virus variants
could be selected with a severely truncated lhNef hairpin
structure [28]. These escape variants are listed in Figure
1B, with the number of basepairs in the remaining hairpin
structure in their name. For instance, AS44 has 44 remain-
ing basepairs, producing a hairpin of intermediate stabil-
ity (ΔG = - 84.7 kcal/mol). We now set out to test these
variants in further detail, e.g. for their ability to inhibit
wild-type HIV-1 in trans.
Trans-inhibition of wild-type HIV-1
HEK293T cells were transfected with the wild type HIV-1
construct or HIV-lhNef. We measured CA-p24 in the cul-
ture supernatant as a measure of virus production 2 days
post-transfection. Whereas wild-type HIV-1 produced
high CA-p24 levels, no virus production was detected for
HIV-lhNef (Fig. 2A, upper panel). This loss of virus pro-
duction is due to the presence of the lhNef hairpin
because no such effect was scored for several control con-
structs: HIV-1 with a CMV insertion in sense and antisense
orientation (HIV-CMV and HIV-asCMV) and the Nef-
deleted HIV-1 construct R1 (Fig. 2A). Notably, HIV-
asCMV did not produce high CA-p24 values probably due
to promoter interference from the strong CMV promoter.
We next co-transfected equal amounts of wild-type HIV-1Retrovirology 2007, 4:15 http://www.retrovirology.com/content/4/1/15
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The HIV-lhNef RNA genome encodes an extended hairpin that is truncated by virus evolution Figure 1
The HIV-lhNef RNA genome encodes an extended hairpin that is truncated by virus evolution. (A) The proviral DNA genome, 
highlighting the insertion of the antisense asNef fragment (original Nef coordinates +8544 to +8844). The primers tTA1 and 
CN1 used to amplify the inverted repeat region are indicated. The inverted repeat (thick arrows) results in the formation of a 
300 bp hairpin structure in the RNA genome of HIV-lhNef (middle panel). This hairpin encompasses the polypurine tract (ppt). 
The truncated hairpin structure that emerged by virus evolution is shown in the lower panel. (B) HIV-lhNef escape variants 
were previously described in detail [28]. The name AS (antisense) reflects the number of basepairs in the remaining RNA hair-
pin. ΔG is the thermodynamic stability of the remaining perfectly basepaired stem segment. The replication column shows the 
replication capacity of the viruses.
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with HIV-lhNef, HIV-CMV, HIV-asCMV or R1 (Fig. 2A,
lower panel). Interestingly, only HIV-lhNef was able to
potently inhibit wild-type HIV-1 production in trans. The
level of inhibition is comparable to that obtained in a co-
transfection with the highly effective shNef inhibitor [9],
which we used as a positive control. We next titrated the
HIV-lhNef construct to test if the inhibitory effect is con-
centration-dependent (Fig. 2B). We measured 92% inhi-
bition of wild-type virus production when mixed 2:1 with
the HIV-lhNef inhibitory construct. Even at a 7:1 ratio,
HIV-1 production was reduced by 61%. The mechanism
of this potent inhibition is currently unknown. Although
HIV-lhNef may be a potently interfering construct, a
major problem is that it does not replicate.
Replication properties of the escape viruses
We studied the replication potential of HIV-lhNef and the
AS escape variants in PBMC (Fig. 3). As a positive control,
the Nef-positive wild-type HIV-1 construct was used. As
shown previously, HIV-lhNef did not replicate to detecta-
ble levels. The escape variant AS44, with the intermediate
length hairpin, replicated only marginally. All other AS
variants replicated efficiently (results are summarized in
Figure 1B), although these variants reached maximal CA-
p24 values at least 1 log lower than that of wild-type HIV-
1. This phenotypic difference can be explained by the Nef-
minus genotype of these viral strains as the accessory Nef
protein contributes to efficient virus replication in pri-
mary cells [30,31].
We next transfected the plasmid constructs encoding wild-
type HIV-1, HIV-lhNef and the AS escape variants in
HEK293T cells. These cells do not support HIV-1 replica-
tion, but produce virus particles upon DNA transfection.
Virus production was measured by CA-p24 ELISA in the
culture supernatant at three days post-transfection. Unlike
the original HIV-lhNef mutant, which demonstrated a
severe CA-p24 production defect, all AS variants effi-
ciently produced virus (Fig. 4A). This result demonstrates
that truncation of the lhNef hairpin overcomes the pro-
duction and replication defect. We next tested if the AS
variants are able to inhibit wild-type HIV-1 in trans in the
co-transfection assay. Compared to the effective HIV-
lhNef inhibitor, all AS escape variants had lost the ability
to actively inhibit wild-type virus production (Fig. 4B).
Even the poorly replicating AS44 variant lost the capacity
to inhibit HIV-1 in trans. Thus, the capacity of HIV-lhNef
to inhibit HIV-1 correlates with its replication defect.
Virus competition between HIV-1 and the HIV-lhNef 
escape variants
As a more sensitive assay for possible trans-inhibition, we
tested the individual AS variants in a direct competition
with wild-type HIV-1 in PBMC. Cells were infected with
an equimolar mixture of the two viruses (based on CA-
p24) that were produced in HEK293T cells, and virus was
passaged to fresh cells at the peak of infection. Virus repli-
cation was monitored by CA-p24 ELISA and visual inspec-
tion for syncytia. Cellular DNA was extracted at several
times post-infection and the proviral Nef region was PCR
amplified with primers tTA1 and CN1 (see Fig. 1). Since
the PCR products will differ in size for wild-type HIV-1
and each AS variant, both competitors can be detected in
the same sample by subsequent agarose gel electrophore-
sis of the DNA fragments. The outgrowth of a particular
virus was verified by cloning and sequencing of the PCR
products from the last time-point sample (results not
shown).
Wild-type HIV-1 effectively outcompeted all AS mutants
in PBMC. An example of the competition between HIV-1
and the AS19 variant is provided in Figure 5A. Both
viruses are detected in the culture at day 5, but we
observed a gradual increase in the intensity of the larger
PCR product. A single PCR product was observed at day
58, indicating that HIV-1 predominated the culture and
thus effectively outcompeted AS19. The same result was
obtained when HIV-1 and AS19 were mixed in a 1:10 ratio
(Fig. 5B). The competition results for all AS variants are
summarized in Table 1 and shown in Additional file 1.
The AS variants are likely to be less replication competent
than wild-type HIV-1 due to the Nef-minus genotype, but
the remnant hairpin structure may also impose a negative
effect on the replication capacity. We therefore included
the unrelated Nef-minus mutant R1 with a 106 nt dele-
tion in Nef, but without a hairpin structure [9]. R1 pro-
duces CA-p24 levels comparable to wild-type HIV-1 and
cannot inhibit viral production in trans (Fig. 2 and 4). We
performed competition experiments between HIV-1 and
R1, but also with AS19 and R1. HIV-1 also outcompetes
the alternative Nef-minus R1 mutant (Fig. 5C). AS19 and
R1 co-existed in the culture up to 62 days post-infection
(Fig. 5C), indicating that both Nef-minus viruses have
very similar replication fitness.
We repeated the competition experiments in the SupT1 T
cell line. Because the Nef protein has no impact on viral
replication fitness in T cell lines [30], this system may
allow a more sensitive screen for trans-inhibition of wild-
type HIV-1 by the hairpin-containing AS variants. In fact,
all AS mutants outcompeted wild-type HIV-1, as illus-
trated for the AS19 variant (Fig. 6A). The results for all AS
variants are summarized in Table 1 and shown in Addi-
tional files 1, 2 and 3. Intriguingly, variant R1 co-existed
with the wild-type virus for 62 days (Fig. 6B). This result
confirms that the Nef function is not important in T cell
lines. However, because the AS variants were able to out-
compete HIV-1, it raises the interesting possibility of hair-
pin-mediated (trans) inhibition by these AS variants.
Perhaps even more surprisingly, AS19 and R1 co-existedRetrovirology 2007, 4:15 http://www.retrovirology.com/content/4/1/15
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Trans-inhibition of HIV-1 by HIV-lhNef Figure 2
Trans-inhibition of HIV-1 by HIV-lhNef. (A) HEK239T cells were co-transfected with 150 ng of the HIV-1 molecular clone LAI, 
HIV-lhNef, HIV-CMV, HIV-asCMV or R1 and 150 ng pBluescript (Promega) (upper panel). In the lower panel 150 ng HIV was 
co-transfected with 150 ng pSuper-shNef, HIV-lhNef, HIV-CMV, HIV-asCMV or R1. 1 ng pRL plasmid, expressing Renilla luci-
ferase from the CMV promoter was added as an internal control for cell viability and transfection efficiency. Transfections 
were performed with lipofectamine-2000 and 1.5 × 105 cells. Virus production was measured in the culture supernatant 2 days 
after transfection by CA-p24 ELISA and Renilla expression was measured with the Renilla luciferase assay system (Promega). 
We plotted the relative percentage of CA-p24/RL, with the HIV + pBluescript transfection set at 100%. Error bars represent 
the standard deviation from quadruple transfections in three independent experiments. (B) Titration of the HIV-lhNef inhibi-
tor. 500 ng HIV-1 was co-transfected with increasing amounts (0-75-125-250-500 ng) of HIV-lhNef. The total DNA concentra-
tion was kept constant by adding pBluescript. Virus production was measured in the culture supernatant 2 days after 
transfection. Error bars represent the standard deviation in three replicates. This is a representative figure from three transfec-
tion experiments with similar results.
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for the length of the competition experiment. We specu-
late that the deletion mutant R1 may lack target sequences
for trans-inhibition by AS19.
Mechanism of trans-inhibition by HIV-lhNef and the AS 
variants
We have previously described strong inhibition of HIV-1
by RNAi-inducing expression vectors encoding shRNA or
lhRNA molecules directed against viral genes
[9,13,14,18]. One possibility is that the mechanism of
HIV-1 inhibition by HIV-lhNef or the AS mutants could
be RNAi-related. One of the hallmarks of RNAi is its
sequence-specificity. We therefore tested if HIV-lhNef
could inhibit the Luc-Nef reporter, in which a 250 nt Nef
target sequence was placed downstream of the Photinus
luciferase gene [11]. As a positive control, we showed that
HIV-lhNef induced a dramatic decrease of wild-type HIV-
1 production in trans, comparable in efficiency with the
highly effective RNAi-inducers shGag and shNef [13] (Fig.
7A). However, no sequence-specific inhibition of the Luc-
Nef reporter was obtained with HIV-lhNef (Fig. 7B). The
shGag molecule serves as a negative control in this exper-
iment, and shNef as a potent positive control. In these
transient transfection experiments a Renilla luciferase
expression plasmid was included, which provides a con-
trol for transfection efficiency and possible aspecific
effects. Renilla luciferase expression was similar in all
transfections (results not shown), indicating that HIV-
Virus replication of HIV-lhNef and the escape variants in PBMC Figure 3
Virus replication of HIV-lhNef and the escape variants in PBMC. Cells (5 × 106) were transfected with 10 μg of the proviral 
DNA constructs and CA-p24 production was measured in the culture supernatant at several days post-transfection for up to 4 
weeks. Half of the culture medium was replaced with fresh complete RPMI medium with IL-2 every 4 days and freshly activated 
PBMC (2 × 106) were added at every 2nd addition. The experiment has been repeated five times for AS19 and two times for 
the other variants.
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Virus production of the HIV-lhNef escape variants and trans-inhibition of HIV-1 Figure 4
Virus production of the HIV-lhNef escape variants and trans-inhibition of HIV-1. (A) Virus production in HEK293T cells. Cells 
were transfected with 150 ng pBluescript and 150 ng of the indicated constructs. 1 ng pRL plasmid was added as an internal 
control. Transfections were performed with lipofectamine-2000 and 1.5 × 105 cells. Virus production was measured in the cul-
ture supernatant 2 days after transfection by CA-p24 ELISA and RL expression was measured with the Renilla luciferase assay 
system (Promega). We plotted the relative percentage of CA-p24/RL, with the transfection HIV + pBluescript set at 100%. 
Error bars represent the standard deviation from quadruple transfections in two independent experiments. (B) Trans-inhibi-
tion of HIV-1 production by the AS escape mutants. HEK293T cells were co-transfected with 150 ng HIV-1 and 150 ng pSuper-
shNef, HIV-lhNef, the AS escape mutants or R1. CA-p24 production was measured in the culture supernatant at two days 
post-transfection. Error bars represent the standard deviation from quadruple transfections in two independent experiments.
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Virus competition experiments in PBMC Figure 5
Virus competition experiments in PBMC. (A) Two viruses were mixed as indicated on top of the panels, usually in a 1:1 ratio 
(unless indicated otherwise, see panel B). The composition of the virus mixture was followed by PCR across the Nef region 
with primers tTA1 and CN1 (see Fig. 1A). The experiment has been repeated 5 times for AS19. Appropriate markers and 
molecular weight standard (M) are indicated. The identity of the respective PCR fragments is indicated on the right. (B) Com-
petition of HIV-1 and AS19 mixed in three ratios: 10:1, 1:1, 1:10. (C) Competition between the R1 variant and either HIV-1 or 
AS19. R1 is a 106 nt Nef deletion mutant. The experiment has been repeated twice, with similar results.
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lhNef mediated inhibition of HIV-1 is specific and not
due to non-specific effects, e.g. due to IFN induction by
dsRNA.
Conclusion
In this study, we show that HIV-1 expressing an exces-
sively stable 300 bp lhNef hairpin potently inhibits wild-
type HIV-1 in trans. However, HIV-lhNef did not replicate
to detectable levels in HIV-1 target cells, probably because
steps of its replication cycle are affected by the hairpin
insertion, e.g. RNA splicing, RNA nuclear export or mRNA
translation. Moreover, HIV-lhNef may cause degradation
of its own mRNA due to processing by the RNAi machin-
ery. We postulate that the lhNef hairpin may induce an
antiviral response against wild-type HIV-1 either through
a sequence-specific RNAi mechanism or through aberrant
HIV-1 transcripts lacking the 3' non-coding region and
polyA tail that induce a potent HIV-1-specific RNA silenc-
ing response in cells. Tests with reporter constructs do not
support a sequence-specific RNAi effect, although the
effect induced by lhNef is HIV-1 specific. The mechanism
of trans-inhibition is currently unknown, but it remains of
interest to study the molecular details because the
observed inhibition is extremely potent. We are currently
dissecting the mechanism of inhibition by testing HIV-
lhNef variants that lack important RNA signals (TAR,
polyA, PAS, PBS, DIS, SD, psi).
Although HIV-lhNef is a potent inhibitor of wild-type
HIV-1, its inability to replicate precluded long-term inhi-
bition experiments. After prolonged culturing of HIV-
lhNef, replicating variants emerged through recombina-
tion events that introduce large truncations in the lhNef
hairpin structure and therefore deletions in the Nef gene.
Interestingly, all AS variants inherit a part of the hairpin
structure in their genome, there were no perfect deletions
of the entire lhNef region. One could speculate that the
remaining secondary RNA structures are actively selected
because they render the viral genome less susceptible for
degradation by the RNAi machinery [11].
Nef represents a pathogenicity factor that disorders adap-
tive immunity by down regulating CD4 and MHC-1
receptors, by inhibiting T-cell chemotaxis, and by induc-
ing apoptosis in bystander T-cells, and hence plays a
major role in the destruction of the host immune system
[32,33]. It has been suggested that any therapeutic inter-
vention aimed at either completely blocking or at least
partially reducing the expression of Nef during HIV-1
infection would likely enhance the ability of the immune
system to fight HIV infection [34]. Humans infected with
Nef-defective HIV-1 strains show low viral loads and no or
very slow disease progression and represent long-term
non-progressors or long-term slow-progressors [31,35].
Moreover, macaques vaccinated with a SIV strain that only
lacks Nef are better protected against superinfection than
macaques vaccinated with a SIV strain lacking the three
accessory genes Nef, Vpr and Vpx [36]. The cross-protec-
tion conferred by the attenuated SIV strains appears not to
be based on stimulation of the adaptive immune system,
but on other (unknown) mechanisms [37]. In this study,
we demonstrate effective outgrowth of the Nef-minus AS
escape variants in competitions with wild-type HIV-1.
This result was obtained in the SupT1 T cell line, which
does not provide a clear Nef-phenotype. We think that
this outcompetition is related to the presence of the
genomic hairpin structure, because no such effect was
observed for the control Nef-deletion virus R1. These in
vitro results may relate to the superior protection with
Nef-deleted viruses in vivo.
Successful expression of a shRNA from a replicating viral
vector has been shown for Rous sarcoma virus (RSV) in
avian cells [38]. We previously described inhibition of
HIV-1 replication by a conditional-live HIV-rtTA virus that
expresses a shRNA against the Nef gene [27]. This
approach is especially suitable for targeting cells that are
susceptible to HIV-1 infection. However, HIV-1 escape
variants will emerge rapidly under shNef pressure [9].
Expression of multiple shRNAs or a single lhRNA from
such a vector could prevent viral escape because multiple
Table 1: Pairwise virus competition experiments
Virus mix a PBMC winner SupT1 winner
HIV/AS44 HIV (4)b HIV (4)
HIV/AS19 HIV (58) AS19 (12)
HIV/AS15 HIV (23) AS15 (23)
HIV/AS11 HIV (23) AS11 (33)
HIV/AS6 HIV (11) AS6 (16)
HIV/R1 HIV (52) HIV/R1 (>62)
AS19/R1 AS19/R1 (>62) AS19/R1 (>62)
a the same virus mix was tested on PBMC and SupT1 cells
b the day of outgrowth (>90%) is indicated between brackets; the experiment has been repeated five times for AS19 and two times for the other 
variantsRetrovirology 2007, 4:15 http://www.retrovirology.com/content/4/1/15
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precise mutations should occur. Use of a murine leukemia
virus (MLV) can also be used for efficient and stable deliv-
ery of anti-HIV-1 shRNA [39]. However, MLV can replicate
only in actively dividing cells, which limits its application
as a therapeutic virus.
One ideal property of replicating HIV-1-based viral vec-
tors is that they specifically target HIV-1 susceptible cells.
The replication-competent AS escape variants lost the
trans-inhibitory properties of HIV-lhNef, but effectively
outcompeted wild-type HIV-1 in T cells. It is important to
asses what is the minimum length of a hairpin that can
mediate trans-inhibition of wild type HIV-1. We have pre-
viously shown that a 19 nt shRNA expressed from condi-
tionally replicating HIV-1-based virus, can inhibit viral
replication [27]. Any hairpin longer than that should in
theory mediate trans-inhibition of HIV-1. Further research
is needed to see if we can design constructs that are repli-
cation competent, yet remain a potent trans-inhibitor of
HIV-1. For example, a lhRNA variant with G-U wobbles
could be designed, which will destabilize the RNA struc-
ture and therefore stimulate viral replication. Such an
approach using 90–100 bp lhRNA molecules has been
suggested as a means for intracellular immunisation
Virus competition experiments in the SupT1 T cell line Figure 6
Virus competition experiments in the SupT1 T cell line. See legend to Fig. 5 for details. (A) Competition between HIV-1 and 
AS19. (B) Competition between the R1 variant and either HIV-1 or AS19.
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Test of sequence-specificity of the inhibition by HIV-lhNef Figure 7
Test of sequence-specificity of the inhibition by HIV-lhNef. (A) Trans-inhibition of HIV-1 production by HIV-lhNef and the 
RNAi-inducing shGag or shNef constructs. HEK293T cells were co-transfected with 100 ng HIV-1 and 100 ng pBluescript, 100 
ng HIV-lhNef, shGag or shNef. CA-p24 production was measured in the culture supernatant at two days post-transfection. 
Error bars represent the standard deviation in two independent experiments. (B) Inhibition of the Luc-Nef reporter. HEK 
239T cells were co-transfected with 100 ng of Luc-Nef and 100 ng HIV-1, HIV-lhNef, shGag or shNef. Error bars represent the 
standard deviation in two independent experiments.
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against HBV and HCV, without evoking non-specific IFN
responses [19,40]. Such constructs could form the basis
for an attenuated virus vaccine and anti-HIV therapeutic
virus in one.
Materials and methods
DNA constructs and proviral DNA analysis
The full-length molecular HIV-1 clone LAI [41] (Accession
number AF33819.3) was used to produce wild-type virus.
HIV-lhNef has a 93 nt deletion in the 5' region of Nef and
a 300 bp inverted repeat within the Nef gene (Fig. 1). The
construction of the HIV-lhNef mutant and the generation
of molecular clones of HIV-lhNef escape virus variants
AS44, AS19, AS15, AS11 and AS8 has been described pre-
viously [28]. The HIV-1 mutant R1 has a 106 nt deletion
in Nef (+8513 to +8619) and has been described previ-
ously [9]. HIV-CMV and HIV-asCMV were constructed by
inserting the CMV promoter in sense or antisense orienta-
tion at position +8069 of the LAI genome. pSuper-shGag
and pSuper-shNef with the H1 polymerase III promoter
have been described previously [13]. Nucleotide numbers
refer to the position on the genomic HIV-1 RNA tran-
script, with +1 being the capped G residue. Plasmid pGL3-
Nef (Luc-Nef), in which 250 nt from the Nef gene was
placed downstream of the Photinus  luciferase reporter
gene has been described previously [11].
For cellular DNA isolation, cells were pelleted for 4 min at
4000 rpm and solubilized in 150 μl lysis buffer (10 mM
Tris-HCl pH 8.0, 1 mM EDTA, 0.5 % Tween 20) and 200
μg/ml proteinase K (Roche) at 56°C for 1 h and at 95°C
for 10 min. Proviral DNA sequences were PCR amplified
from 5 μl cellular lysate using the 5' Env primer tTA1-AD
(+8269 to +8289, ACA GCC ATA GCA GTA GCT GAG)
and 3' U5 primer CN1 (+9283 to +9253, GGT CTG AGG
GAT CTC TAG TTA CCA GAG TC) (Fig. 1). PCR amplifica-
tion was performed in a 50 μl reaction containing 1 × PCR
amplification buffer (Invitrogen), 0.5 mM MgCl2, 25
pmol of each primer, 0.2 mM dNTPs and 2.5 units of
AmpliTaq DNA polymerase (Perkin Elmer Applied Bio-
system). The PCR program was as follows: 95°C for 5
min, 30 cycles of 30 sec at 94°C, 30 sec at 55°C, 30 sec at
72°C, and a final extension for 7 min at 72°C. The PCR
products were separated on a 1% agarose gel stained with
ethidium bromide and compared to a standard DNA size
marker (Eurogentec). HIV-lhNef could not be amplified
with this PCR due to the extended inverted repeat that
may form a cruciform DNA structure. The RNA structures
formed by HIV-lhNef and the AS escape variants were pre-
dicted with the Mfold program [42].
Cells, DNA transfection and virus infection
Human embryonic kidney (HEK) 293T cells were grown
as a monolayer in DMEM (Invitrogen) supplemented
with 10% FCS, minimal essential medium nonessential
amino acids, penicillin (100 U/ml) and streptomycin
(100 μg/ml) at 37°C and 5% CO2. One day before trans-
fection, cells were trypsinized, resuspended in DMEM and
seeded in 24-well plates at a density of 1.5 × 105 cells per
well. Cells were co-transfected with 100 – 500 ng DNA
with Lipofectamine 2000 (Invitrogen) according to the
manufacturer's instructions. 1 ng pRL plasmid (Promega),
expressing Renilla luciferase (RL) from the CMV pro-
moter, was added as an internal control for cell viability
and transfection efficiency. In all transfection experiments
we have controlled for the DNA input by adding pBlue-
script (Promega) to reach identical DNA concentrations.
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from buffy coats by standard Ficoll-Hypaque density
centrifugation, activated with phytohemagglutinin (3 μg/
ml), and cultured in complete RPMI 1640 medium (Inv-
itrogen) with IL-2 (100 U/ml). Cells (5 × 106) were trans-
fected with 10 μg of the proviral DNA by electroporation
in 250 μl RPMI with 20% FCS in 0.4-cm cuvettes at 250 V
and 960 μF, and 1 × 106 fresh cells and 5 ml complete
RPMI with IL-2 were added afterwards. PBMCs were
infected with a fixed amount (5 ng CA-p24) of 293T-pro-
duced virus and maintained for up to 4 weeks. Half of the
culture medium was replaced every 4 days by fresh com-
plete RPMI 1640 medium with IL-2 and freshly activated
PBMC (2 × 106) were added at every 2nd addition.
The human T cell line SupT1 was cultured in RPMI 1640
medium supplemented with 10% fetal calf serum (FCS)
(Hybond), penicillin (100 U/ml) and streptomycin (100
μg/ml) at 37°C and 5% CO2. Cells were cultured in 25
cm2 flasks and split 1 to 10 twice a week. Cells were
infected with equal amounts (5 ng CA-p24) of 293T-pro-
duced virus. When HIV-induced cytopathic effects were
observed, virus replication was maintained by passage of
the cell-free culture supernatant onto uninfected SupT1
cells. At each passage, cell and supernatant samples were
stored at -70°C. Virus spread was followed by CA-p24
ELISA on the culture supernatant as described previously
[43] and Renilla expression was measured with the
Renilla luciferase assay system (Promega).
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